Cardiovascular toxicity of chemotherapy and thyroid status of patients with gastric and colon cancer: Current state of the problem. A review

Cover Page

Cite item

Full Text

Abstract

Cardiovascular and oncological diseases are the main causes of disability and mortality in Russia, sharing common risk factors and exacerbating each other. The specific toxicological effects of fluoropyrimidines, platinum drugs, and taxanes commonly used in the treatment of gastric and colorectal malignancies have been noted to potentially contribute to the onset of cardiovascular pathologies in some cases. However, the manifestation and prevalence of cardiovascular toxicity due to cancer treatment regimens are influenced by various factors beyond just the chemotherapy protocols employed. Gender, age, overall health status (including cardiac and thyroid functions), and other risk factors play significant roles in the development and progression of heart and vascular diseases in these patients. Thyroid dysfunction, even in the absence of severe clinical symptoms, can significantly impact the course of cardiovascular pathologies, complicating the management of toxic effects associated with polychemotherapy on both the cardiac muscle and vascular system. This paper analyzes modern ideas about pathogenetic relationship between cardiovascular diseases and gastric and colon cancer. The profile and mechanism of cardiovascular toxicity of chemotherapy in patients with gastric and colon cancer, pathogenetic relationship of thyroid status and cardiovascular diseases are presented. Organizational management issues of chemotherapy toxicity are briefly highlighted.

About the authors

Irina V. Stanoevich

Kursk State Medical University; Endocrinology Research Center

Email: alina.vetrova1999@gmail.com
ORCID iD: 0000-0002-9681-672X

D. Sci. (Med.), Assoc. Prof.

Russian Federation, Kursk; Moscow

Vitaliy A. Ioutsi

Endocrinology Research Center

Email: alina.vetrova1999@gmail.com
ORCID iD: 0000-0001-9002-1662

Cand. Sci. (Chem.)

Russian Federation, Moscow

Natalya L. Lysovolenko

Ostroverkhov Kursk Oncological Research and Clinical Center

Email: alina.vetrova1999@gmail.com
ORCID iD: 0000-0001-7747-2784

Head Department

Russian Federation, Kursk

Ilya E. Alekseev

Ostroverkhov Kursk Oncological Research and Clinical Center

Email: alina.vetrova1999@gmail.com
ORCID iD: 0000-0003-3745-0307

cardiologist

Russian Federation, Kursk

Alina D. Kondrashkina

Kursk State Medical University

Author for correspondence.
Email: alina.vetrova1999@gmail.com
ORCID iD: 0009-0009-9271-7810

resident

Russian Federation, Kursk

Maksim B. Polianskii

Ostroverkhov Kursk Oncological Research and Clinical Center

Email: alina.vetrova1999@gmail.com
ORCID iD: 0000-0002-5996-6024

Cand. Sci. (Med.)

Russian Federation, Kursk

Ekaterina V. Pis'mennaia

Ministry of Health of the Kursk Region

Email: alina.vetrova1999@gmail.com
ORCID iD: 0009-0004-6417-1949

 Cand. Sci. (Med.)

Russian Federation, Kursk

References

  1. Karlstaedt A, Moslehi J, de Boer RA. Cardio-onco-metabolism: Metabolic remodelling in cardiovascular disease and cancer. Nat Rev Cardiol. 2022;19(6):414-25. doi: 10.1038/s41569-022-00698-6
  2. Boudoulas KD, Triposkiadis F, Gumina R, et al. Cardiovascular disease, cancer, and multimorbidity interactions: Clinical implications. Cardiology. 2022;147(2):196-206. doi: 10.1159/000521680
  3. Chan AO, Jim MH, Lam KF, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA. 2007;298(12):1412-9. doi: 10.1001/jama.298.12.1412
  4. Nonaka M, Hosoda H, Uezono Y. Cancer treatment-related cardiovascular disease: Current status and future research priorities. Biochem Pharmacol. 2021;190:114599. doi: 10.1016/j.bcp.2021.114599
  5. de With M, Sadlon A, Cecchin E, et al. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open. 2023;8(2):101197. doi: 10.1016/j.esmoop.2023.101197
  6. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Cтаринского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-v-rossii-v-2021-g_zabolevaemost-i-smertnost.pdf. Ссылка активна на 05.10.2023 [Zlokachestvennye novoobrazovaniia v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITs radiologii” Minzdrava Rossii, 2022. Available at: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-v-rossii-v-2021-g_zabolevaemost-i-smertnost.pdf. Accessed: 05.10.2023 (in Russian)].
  7. Рак желудка. Клинические рекомендации Минздрава России. Режим доступа: https://old.oncology-association.ru/clinical-guidelines. Ссылка активна на 05.10.2023 [Rak zheludka. Klinicheskie rekomendatsii Minzdrava Rossii. Available at: https://old.oncology-association.ru/clinical-guidelines-update. Accessed: 05.10.2023 (in Russian)].
  8. Рак ободочной кишки. Клинические рекомендации Минздрава России. Режим доступа: https://old.oncology-association.ru/clinical-guidelines. Ссылка активна на 05.10.2023 [Rak obodochnoi kishki. Klinicheskie rekomendatsii Minzdrava Rossii. Available at: https://old.oncology-association.ru/clinical-guidelines. Accessed: 05.10.2023 (in Russian)].
  9. Рак прямой кишки. Клинические рекомендации Минздрава России. Режим доступа: https://old.oncology-association.ru/clinical. Ссылка активна на 05.10.2023 [Rak priamoi kishki. Klinicheskie rekomendatsii Minzdrava Rossii. Available at: https://old.oncology-association.ru/clinical-guidelines. Accessed: 05.10.2023 (in Russian)].
  10. Станоевич У.С., Горелик С.Г., Звягин И.Н., и др. Распространенность колоректального рака у пациентов старших возрастных групп. Современные проблемы здравоохранения и медицинской статистики. 2021;4:235-50 [Stanoevich US, Gorelik SG, Zvyagin IN, et al. Prevalence of colorectal cancer in older age patients. Current Problems of Health Care and Medical Statistics. 2021;4:235-50 (in Russian)]. doi: 10.24412/2312-2935-2021-4-235-250
  11. Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-361. doi: 10.1093/eurheartj/ehac244
  12. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: A scanning microscopy evaluation. Scanning. 2001;23(1):1-8. doi: 10.1002/sca.4950230101
  13. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53(13):3028-33. PMID: 8391384
  14. Focaccetti C, Bruno A, Magnani E, et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015;10(2):e0115686. doi: 10.1371/journal.pone.0115686
  15. Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer. 2009;8(4):231-4. doi: 10.3816/CCC.2009.n.039
  16. Goncharov NV, Jenkins RO, Radilov AS. Toxicology of fluoroacetate: a review, with possible directions for therapy research. J Appl Toxicol. 2006;26(2):148-61. doi: 10.1002/jat.1118
  17. Kostis WJ, Sargsyan D, Mekkaoui C, et al. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. J Hum Hypertens. 2019;33(10):735-40. doi: 10.1038/s41371-019-0180-4
  18. El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol. 2011;650(1):335-41. doi: 10.1016/j.ejphar.2010.09.085
  19. Ma H, Jones KR, Guo R, et al. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: Role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol. 2010;37(4):460-5. doi: 10.1111/j.1440-1681.2009.05323.x
  20. Madeddu C, Deidda M, Piras A, et al. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med (Hagerstown). 2016;17(Suppl. 1):S12-8. doi: 10.2459/JCM.0000000000000376
  21. Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: A review. Drug Saf. 2015;38(2):129-52. doi: 10.1007/s40264-014-0258-4
  22. Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther. 2006;318(1):424-33. doi: 10.1124/jpet.106.103846
  23. Accorroni A, Saponaro F, Zucchi R. Tissue thyroid hormones and thyronamines. Heart Fail Rev. 2016;21(4):373-90. doi: 10.1007/s10741-016-9553-8
  24. Sabatino L, Vassalle C, Del Seppia C, Iervasi G. Deiodinases and the three types of thyroid hormone deiodination reactions. Endocrinol Metab (Seoul). 2021;36(5):952-64. doi: 10.3803/EnM.2021.1198
  25. Quiroz-Aldave JE, Durand-Vásquez MDC, Lobato-Jeri CJ, et al. Thyrotoxic cardiomyopathy: State of the art. TouchREV Endocrinol. 2023;19(1):78-84. doi: 10.17925/EE.2023.19.1.78
  26. Pedraza PE, Obregon MJ, Escobar-Morreale HF, et al. Mechanisms of adaptation to iodine deficiency in rats: Thyroid status is tissue specific. Its relevance for man. Endocrinology. 2006;147(5):2098-108. doi: 10.1210/en.2005-1325
  27. Trivieri MG, Oudit GY, Sah R, et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci USA. 2006;103(15):6043-8. doi: 10.1073/pnas.0601072103
  28. Bianco AC, Kim BW. Deiodinases: Implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571-9. doi: 10.1172/JCI29812
  29. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: An adaptative response or part of the problem? Heart Fail Rev. 2010;15(2):133-42. doi: 10.1007/s10741-008-9133-7
  30. Хроническая сердечная недостаточность. Клинические рекомендации Минздрава России. Режим доступа: https://cr.minzdrav.gov.ru/schema/156_1. Ссылка активна на 08.07.2023 [Khronicheskaia serdechnaia nedostatochnost’. Klinicheskie rekomendatsii Minzdrava Rossii. Available at: https://cr.minzdrav.gov.ru/schema/156_1. Accessed: 08.07.2023 (in Russian)].
  31. Iervasi G, Pingitore A, Landi P, et al. A strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107(5):708-13. doi: 10.1161/01.cir.0000048124.64204.3f
  32. Джанашия П.Х., Селиванова Г.Б. Артериальная гипертензия при тиреотоксикозе: вопросы нейрогуморальной активации, гемодинамических и метаболических изменений. Российский кардиологический журнал. 2004;(1):73-9 [Dzhanashija PK, Selivanova GB. Arterial hypertension in thyrotoxicosis: Neurohumoral regulation, hemodynamic and metabolic changes. Russian Journal of Cardiology. 2004;(1):73-9 (In Russian)].
  33. Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Regulation of DIO3 expression and cardiomyocyte remodeling [29].

Download (190KB)
Indexing metadata

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies